Basilea to get £146 million for eczema drug

Basilea Pharmaceutica Ltd is to receive £146 million upfront from Stiefel, a unit of GlaxoSmithKline Plc, for an eczema compound. It will use the proceeds to support the development and registration of its candidate antibiotic and antifungal drugs.